Literature DB >> 6214992

Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin.

B Lutz, W Mogabgab, B Holmes, B Pollock, R Beville.   

Abstract

The efficacy and tolerance of parenterally administered piperacillin were evaluated in 50 adult patients hospitalized with systemic and urinary tract infections. Dosage for 46 patients was 4 to 12 g daily and for 4 patients, 16 to 24 g daily; in each case divided doses were given every 4 to 6 h. The duration of treatment for most patients was 5 to 10 days. Of the 50 patients, 45 (90%) were considered cured, and 57 (89%) of the 64 pathogens isolated were eradicated by piperacillin treatment. Side effects, reported by 12 patients, were mild to moderate in degree and consisted of vein irritation, thrombophlebitis, pain at the injection site, and diarrhea, Piperacillin appears to be a highly effective antibiotic for treating infections caused by susceptible gram-positive and gram-negative microorganisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214992      PMCID: PMC183665          DOI: 10.1128/AAC.22.1.10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro and in vivo activity of piperacillin, a new broad-spectrum semisynthetic penicillin.

Authors:  N A Kuck; G S Redin
Journal:  J Antibiot (Tokyo)       Date:  1978-11       Impact factor: 2.649

2.  Comparative evaluation of piperacillin in vitro.

Authors:  G M Dickinson; T J Cleary; T A Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

3.  Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: carbenicillin, piperacillin, and ticarcillin.

Authors:  G R Monif; P R Clark; J J Shuster; H Baer
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

4.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

6.  Susceptibility of cephalothin-resistant gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics.

Authors:  W L George; R P Lewis; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.

Authors:  R N Jones; R R Packer; A L Barry; R E Badal; C Thornsberry; C Baker
Journal:  J Antibiot (Tokyo)       Date:  1979-01       Impact factor: 2.649

8.  In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics.

Authors:  T D Gootz; C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

  8 in total
  4 in total

1.  Clinical comparison of piperacillin and cefoxitin in patients with bacteriologically confirmed infections.

Authors:  R V McCloskey
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; D N McKinstry
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

Review 3.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

4.  Piperacillin induced bone marrow suppression: a case report.

Authors:  Ashish Kumar; Gourdas Choudhuri; Rakesh Aggarwal
Journal:  BMC Clin Pharmacol       Date:  2003-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.